Genmab A/S (OTCMKTS:GNMSF) Sees Large Drop in Short Interest

Genmab A/S (OTCMKTS:GNMSF) was the recipient of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 80,900 shares, a decrease of 20.5% from the January 15th total of 101,800 shares. Based on an average trading volume of 21,300 shares, the days-to-cover ratio is presently 3.8 days.

Genmab A/S Stock Up 1.6 %

Shares of GNMSF traded up $3.35 during mid-day trading on Friday, hitting $210.97. 157 shares of the company traded hands, compared to its average volume of 6,895. Genmab A/S has a 1-year low of $186.61 and a 1-year high of $323.02. The company has a market capitalization of $13.94 billion, a PE ratio of 20.29 and a beta of 1.04. The business has a 50 day moving average of $206.28 and a 200 day moving average of $230.43.

Genmab A/S (OTCMKTS:GNMSF) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $5.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $5.24. Genmab A/S had a net margin of 23.49% and a return on equity of 17.73%.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.